Download UNITED STATES SECURITIES AND EXCHANGE - corporate

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): February 27, 2017
Global Blood Therapeutics, Inc.
Delaware
(State or Other Jurisdiction of
Incorporation)
(Exact Name of Registrant as Specified in Charter)
001-37539
27-4825712
(Commission File Number)
(I.R.S. Employer Identification Number)
400 East Jamie Court, Suite 101, South San Francisco, CA 94080
(Address of Principal Executive Offices) (Zip Code)
(650) 741-7700
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
[
[
[
]
]
]
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On February 27, 2017, Global Blood Therapeutics, Inc. issued a press release titled, “Global Blood Therapeutics Announces
Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares” (the “Press
Release”). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release, dated February 27, 2017
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Global Blood Therapeutics, Inc.
Date: February 27, 2017
By:
/s/ Jeffrey Farrow
Jeffrey Farrow
Chief Financial Officer
(Principal Financial Officer)
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release, dated February
27, 2017
EXHIBIT 99.1
Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to
Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT)
(NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
grievous blood-based disorders with significant unmet need, today announced the closing of its previously announced underwritten
public offering of 5,867,347 shares of its common stock at a price to the public of $24.50 per share, which includes 765,306 additional
shares of common stock issued upon the exercise in full of the underwriter’s option to purchase additional shares. The aggregate gross
proceeds to GBT from this offering are $143.8 million, before deducting underwriting discounts and commissions and other estimated
offering expenses payable by GBT. All of the shares in the offering were sold by GBT.
Cantor Fitzgerald & Co. was the sole book-running manager for the offering.
A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the
Securities and Exchange Commission (SEC) on October 14, 2016 and declared effective by the SEC on October 28, 2016. A final
prospectus supplement and accompanying prospectus has been filed with the SEC and copies of the final prospectus supplement and
the accompanying prospectus may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave.,
6 Floor, New York, New York 10022, or by telephone at 212-829-7122, or by email at [email protected].
th
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be
any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and
commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead
product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment
of hypoxemic pulmonary disorders including idiopathic pulmonary fibrosis.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
Pure Communications
415-946-1087
[email protected]